Vivos Therapeutics, FDA
Vivos surges on FDA nod for pediatric sleep apnea device
Vivos Therapeutics (VVOS) stock gains as company receives FDA clearance for its DNA appliance to treat obstructive sleep apnea in children. Read more here.
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive sleep apnea and snoring in children aged 6-17.
Vivos Therapeutics (VVOS) Surges Following Landmark FDA Approval
Vivos Therapeutics is a pioneering medical device and technology company focused on addressing sleep-related breathing disorders (SRBDs), particularly obstructive sleep apnea (OSA). Their flagship product,
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Awarded First-Ever FDA Clearance for Pediatric Treatment of Sleep Apnea, Snoring
Vivos Therapeutics (NASDAQ: VVOS), a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (“SRBDs”) including obstructive sleep apnea (“OSA”) has received breakthrough clearance from the U.
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related ...
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
The gross proceeds to the Company from the offering are expected to be approximately $4.3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The ...
MarketWatch1d
Vivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea Treatment
Vivos Therapeutics shares rose on Wednesday after the company said its oral medical device for pediatric sleep apnea and snoring received 510(k) clearance from the Food and Drug Administration.
FDA Approval Sends Shares of this Healthcare Company Higher
What a session it was for a certain Colorado-based %Healthcare company after it was announced that it received the US Food ...
FDA approves Apple Watch sleep apnea detection tool
The function is not a diagnostic tool, but can tell watch-wearers if they are exhibiting signs of sleep apnea.
Healthline7d
Apple Watch 10 Will Include Sleep Apnea Detection Feature
Apple announced that pending FDA approval, recent versions of the company's popular smartwatches will soon get features that ...
Finanznachrichten1d
Vivos Therapeutics, Inc: Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos' DNA appliance ...